ARTICLE | Clinical News
MORAb-009: Phase II started
March 9, 2009 7:00 AM UTC
Eisai's Morphotek Inc. subsidiary began a single-arm, open-label, international Phase II trial (MORAb-009-003) to evaluate IV MORAb-009 given on days 1 and 8 of a 21-day cycle for 6 cycles plus pemet...